Trustmark National Bank Trust Department reduced its position in Eli Lilly and Company (NYSE:LLY) by 15.9% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 14,349 shares of the company’s stock after selling 2,711 shares during the period. Trustmark National Bank Trust Department’s holdings in Eli Lilly and were worth $1,207,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of LLY. Joel Isaacson & Co. LLC boosted its position in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares during the last quarter. Stephens Inc. AR boosted its position in Eli Lilly and by 4.5% in the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after buying an additional 1,901 shares during the last quarter. Blair William & Co. IL boosted its position in Eli Lilly and by 13.1% in the first quarter. Blair William & Co. IL now owns 262,258 shares of the company’s stock worth $21,974,000 after buying an additional 30,299 shares during the last quarter. Finally, Sabal Trust CO boosted its position in Eli Lilly and by 1.2% in the first quarter. Sabal Trust CO now owns 6,400 shares of the company’s stock worth $538,000 after buying an additional 75 shares during the last quarter. Institutional investors own 75.59% of the company’s stock.

Eli Lilly and Company (NYSE LLY) traded down 0.09% during midday trading on Friday, reaching $78.79. 2,171,482 shares of the company traded hands. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The stock has a market capitalization of $83.12 billion, a P/E ratio of 34.09 and a beta of 0.34. The company has a 50 day moving average price of $81.83 and a 200-day moving average price of $81.93.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. Analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.64%. Eli Lilly and’s payout ratio is 90.04%.

ILLEGAL ACTIVITY WARNING: “Trustmark National Bank Trust Department Has $1.21 Million Stake in Eli Lilly and Company (LLY)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/27/trustmark-national-bank-trust-department-has-1-21-million-stake-in-eli-lilly-and-company-lly.html.

LLY has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and issued a $89.00 price objective (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday. BMO Capital Markets restated an “underperform” rating and issued a $73.00 price objective (up previously from $71.00) on shares of Eli Lilly and in a research report on Saturday, April 29th. Berenberg Bank restated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $87.92.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. Insiders have sold 669,733 shares of company stock worth $55,845,287 over the last 90 days. Insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.